136 related articles for article (PubMed ID: 31115923)
1. Polymorphisms in the promotor region of the CRBN gene as a predictive factor for peripheral neuropathy in the course of thalidomide-based chemotherapy in multiple myeloma patients.
Mlak R; Szudy-Szczyrek A; Mazurek M; Szczyrek M; Homa-Mlak I; Mielnik M; Chocholska S; Jankowska-Łęcka O; Małecka-Massalska T; Hus M
Br J Haematol; 2019 Sep; 186(5):695-705. PubMed ID: 31115923
[TBL] [Abstract][Full Text] [Related]
2. Genetic factors underlying the risk of thalidomide-related neuropathy in patients with multiple myeloma.
Johnson DC; Corthals SL; Walker BA; Ross FM; Gregory WM; Dickens NJ; Lokhorst HM; Goldschmidt H; Davies FE; Durie BG; Van Ness B; Child JA; Sonneveld P; Morgan GJ
J Clin Oncol; 2011 Mar; 29(7):797-804. PubMed ID: 21245421
[TBL] [Abstract][Full Text] [Related]
3. Polymorphisms in the promoter region of the
Szudy-Szczyrek A; Mlak R; Szczyrek M; Chocholska S; Sompor J; Nogalski A; Małecka-Massalska T; Hus M
Oncotarget; 2018 May; 9(35):24054-24068. PubMed ID: 29844872
[TBL] [Abstract][Full Text] [Related]
4. Polymorphisms within beta-catenin encoding gene affect multiple myeloma development and treatment.
Butrym A; Rybka J; Łacina P; Gębura K; Frontkiewicz D; Bogunia-Kubik K; Mazur G
Leuk Res; 2015 Dec; 39(12):1462-6. PubMed ID: 26521987
[TBL] [Abstract][Full Text] [Related]
5. Bortezomib- and thalidomide-induced peripheral neuropathy in multiple myeloma: clinical and molecular analyses of a phase 3 study.
Tacchetti P; Terragna C; Galli M; Zamagni E; Petrucci MT; Pezzi A; Montefusco V; Martello M; Tosi P; Baldini L; Peccatori J; Ruggieri M; Pantani L; Lazzaro A; Elice F; Rocchi S; Gozzetti A; Cavaletti G; Palumbo A; Cavo M
Am J Hematol; 2014 Dec; 89(12):1085-91. PubMed ID: 25159313
[TBL] [Abstract][Full Text] [Related]
6. Thalidomide-based induction regimens are as effective as bortezomib-based regimens in elderly patients with multiple myeloma with cereblon expression.
Jung SH; Choi HJ; Shin MG; Lee SS; Hwang EC; Jung TY; Cho MS; Yang DH; Ahn JS; Kim YK; Kim HJ; Lee JJ
Ann Hematol; 2016 Oct; 95(10):1645-51. PubMed ID: 27365142
[TBL] [Abstract][Full Text] [Related]
7. Features and risk factors of peripheral neuropathy during treatment with bortezomib for advanced multiple myeloma.
El-Cheikh J; Stoppa AM; Bouabdallah R; de Lavallade H; Coso D; de Collela JM; Auran-Schleinitz T; Gastaut JA; Blaise D; Mohty M
Clin Lymphoma Myeloma; 2008 Jun; 8(3):146-52. PubMed ID: 18650177
[TBL] [Abstract][Full Text] [Related]
8. Do baseline Cereblon gene expression and IL-6 receptor expression determine the response to thalidomide-dexamethasone treatment in multiple myeloma patients?
Bedewy AM; El-Maghraby SM
Eur J Haematol; 2014 Jan; 92(1):13-8. PubMed ID: 24118365
[TBL] [Abstract][Full Text] [Related]
9. Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trial.
Popat R; Brown SR; Flanagan L; Hall A; Gregory W; Kishore B; Streetly M; Oakervee H; Yong K; Cook G; Low E; Cavenagh J;
Lancet Haematol; 2016 Dec; 3(12):e572-e580. PubMed ID: 27843120
[TBL] [Abstract][Full Text] [Related]
10. Polymorphism of IL-10 receptor β affects the prognosis of multiple myeloma patients treated with thalidomide and/or bortezomib.
Kasamatsu T; Saitoh T; Ino R; Gotoh N; Mitsui T; Shimizu H; Matsumoto M; Sawamura M; Yokohama A; Handa H; Tsukamoto N; Murakami H
Hematol Oncol; 2017 Dec; 35(4):711-718. PubMed ID: 27405747
[TBL] [Abstract][Full Text] [Related]
11. Pharmacovigilance of patients with multiple myeloma being treated with bortezomib and/or thalidomide.
Castro TB; Hallack Neto AE; Atalla A; Ribeiro LC
Braz J Med Biol Res; 2016; 49(6):e5128. PubMed ID: 27254660
[TBL] [Abstract][Full Text] [Related]
12. Association study of selected genetic polymorphisms and occurrence of venous thromboembolism in patients with multiple myeloma who were treated with thalidomide.
Almasi M; Sevcikova S; Slaby O; Kaisarova P; Maisnar V; Penka M; Pika T; Pour L; Radocha J; Scudla V; Svachova H; Hajek R
Clin Lymphoma Myeloma Leuk; 2011 Oct; 11(5):414-20. PubMed ID: 21859556
[TBL] [Abstract][Full Text] [Related]
13. [Thalidomide induced peripheral neuropathy in multiple myeloma patients].
Banach M; Jurczyszyn A; Skotnicki A
Przegl Lek; 2015; 72(11):629-35. PubMed ID: 27012121
[TBL] [Abstract][Full Text] [Related]
14. Role of the TNF-α promoter polymorphisms for development of multiple myeloma and clinical outcome in thalidomide plus dexamethasone.
Du J; Yuan Z; Zhang C; Fu W; Jiang H; Chen B; Hou J
Leuk Res; 2010 Nov; 34(11):1453-8. PubMed ID: 20122728
[TBL] [Abstract][Full Text] [Related]
15. Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial.
Broyl A; Corthals SL; Jongen JL; van der Holt B; Kuiper R; de Knegt Y; van Duin M; el Jarari L; Bertsch U; Lokhorst HM; Durie BG; Goldschmidt H; Sonneveld P
Lancet Oncol; 2010 Nov; 11(11):1057-65. PubMed ID: 20864405
[TBL] [Abstract][Full Text] [Related]
16. Maintenance Therapy With Immunomodulatory Drugs in Multiple Myeloma: A Meta-Analysis and Systematic Review.
Wang Y; Yang F; Shen Y; Zhang W; Wang J; Chang VT; Andersson BS; Qazilbash MH; Champlin RE; Berenson JR; Guan X; Wang ML
J Natl Cancer Inst; 2016 Mar; 108(3):. PubMed ID: 26582244
[TBL] [Abstract][Full Text] [Related]
17. Cereblon and IRF4 Variants Affect Risk and Response to Treatment in Multiple Myeloma.
Butrym A; Łacina P; Rybka J; Chaszczewska-Markowska M; Mazur G; Bogunia-Kubik K
Arch Immunol Ther Exp (Warsz); 2016 Dec; 64(Suppl 1):151-156. PubMed ID: 28083618
[TBL] [Abstract][Full Text] [Related]
18. Prediction of peripheral neuropathy in multiple myeloma patients receiving bortezomib and thalidomide: a genetic study based on a single nucleotide polymorphism array.
García-Sanz R; Corchete LA; Alcoceba M; Chillon MC; Jiménez C; Prieto I; García-Álvarez M; Puig N; Rapado I; Barrio S; Oriol A; Blanchard MJ; de la Rubia J; Martínez R; Lahuerta JJ; González Díaz M; Mateos MV; San Miguel JF; Martínez-López J; Sarasquete ME;
Hematol Oncol; 2017 Dec; 35(4):746-751. PubMed ID: 27605156
[TBL] [Abstract][Full Text] [Related]
19. Thalidomide-induced neuropathy.
Crawford CL
Mayo Clin Proc; 2002 Dec; 77(12):1395; author reply 1395. PubMed ID: 12479531
[No Abstract] [Full Text] [Related]
20. Thalidomide-induced phrenic nerve paralysis.
Eswedi A; Burnside P; Morris TC
Leuk Lymphoma; 2010 Feb; 51(2):342-4. PubMed ID: 20038224
[No Abstract] [Full Text] [Related]
[Next] [New Search]